AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BEAM · NASDAQ · Biotechnology

Beam Therapeutics (BEAM)

Develops base-edited medicines for sickle cell disease and inherited metabolic disorders.

$26.10

After hours+0.18 (+0.69%)

At close$25.92(+2.61%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	17	316	7	12	14	30	7	8	10	114	32	0
Cost of revenue	100	140	85	87	94	101	99	102	110	6	11	0
Gross profit	−83	176	−77	−75	−80	−71	−91	−93	−100	108	21	0
	25	43	27	30	27	29	28	27	27	126	128	127
Research & development	100	140	85	87	94	101	99	102	110	99	105	95
	25	43	27	30	27	29	28	27	27	27	34	32
General & administrative	25	43	27	30	27	29	28	27	27	27	34	32
Other expenses	−100	−140	−85	−87	−94	−101	−99	−102	−110	0	−11	0
Operating income	−108	133	−104	−105	−107	−100	−119	−120	−127	−17	−107	−127
	12	11	5	14	10	10	10	18	14	262	13	4
Interest income	13	12	12	14	12	11	10	0	11	0	10	7
Interest expense	0	0	0	—	0	0	0	0	0	11	0	0
Other non-operating income	0	−11	−5	−14	−10	−10	−10	−18	−14	−272	−13	4
Income before tax	−96	144	−99	−91	−97	−90	−109	−102	−113	244	−94	−123
Income tax expense	0	1	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−96	143	−99	−91	−97	−90	−109	−102	−113	244	−94	−123
Net income	−96	143	−99	−91	−97	−90	−109	−102	−113	244	−94	−123
EPS, basic	−$1.22	$1.77	−$1.21	−$1.11	−$1.17	−$1.09	−$1.24	−$1.00	−$1.10	$2.37	−$0.91	−$1.18
EPS, diluted	−$1.22	$1.73	−$1.21	−$1.11	−$1.17	−$1.09	−$1.24	−$1.00	−$1.10	$2.33	−$0.91	−$1.18
Weighted average shares, basic	79	81	82	82	82	83	88	102	103	103	103	104
Weighted average shares, diluted	79	83	82	82	82	83	88	102	103	105	103	104
EBITDA	−103	150	−93	−85	−91	−85	−104	−97	−107	261	−89	−125
Depreciation & amortization	5	5	5	6	5	5	6	6	6	6	6	5
EBIT	−108	144	−99	−91	−97	−90	−109	−102	−113	255	−94	−130